Covered recipient · General Payments record
GEORGE DAVID REEDER
Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease
General Payments · PY2018–2024
$2,349.53
- Reported across 89 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $473.60 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GENZYME CORPORATION | $191.18 | 5 |
| Amgen Inc. | $87.07 | 3 |
| Insmed, Inc. | $57.64 | 2 |
| GlaxoSmithKline, LLC. | $52.87 | 2 |
| PFIZER INC. | $26.22 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $22.50 | 1 |
| Grifols USA, LLC | $18.23 | 1 |
| Electromed, Inc. | $17.89 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $30.34 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111686077 | CMS |
| Amgen Inc. | $28.45 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111686079 | CMS |
| Amgen Inc. | $28.28 | 08/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111686081 | CMS |
| Electromed, Inc. | $17.89 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137910862 | CMS |
| GENZYME CORPORATION | $32.58 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139994833 | CMS |
| GENZYME CORPORATION | $33.46 | 10/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139994849 | CMS |
| GENZYME CORPORATION | $29.38 | 10/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139994855 | CMS |
| GENZYME CORPORATION | $26.47 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139994875 | CMS |
| GENZYME CORPORATION | $69.29 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139994881 | CMS |
| GlaxoSmithKline, LLC. | $23.25 | 03/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116090076 | CMS |
| GlaxoSmithKline, LLC. | $29.62 | 06/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116277626 | CMS |
| Grifols USA, LLC | $18.23 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124730561 | CMS |
| Insmed, Inc. | $23.31 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089581722 | CMS |
| Insmed, Inc. | $34.33 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089582676 | CMS |
| Novartis Pharmaceuticals Corporation | $22.50 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087303583 | CMS |
| PFIZER INC. | $26.22 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130986180 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.